FORM 5		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0362 Estimated average burden hours per response: 1.0
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Form 3 Holdings Reported.
X	Form 4 Transactions Reported.

1. Name and Address of Reporting Person* Liu Tony (Last) (First) (Middle) 1345 AVENUE OF THE AMERICAS, FL. 15 (Street) NEW YORK NY 10105 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [ CBMG ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) CEO, CFO
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price
Common Stock(1)	01/25/2019		S4	875	D	$17.69(2)	255,392(12)	D
Common Stock	02/27/2019		S4	875	D	$18.06(3)	254,517(12)	D
Common Stock	03/27/2019		S4	875	D	$16.8(4)	253,642(12)	D
Common Stock	04/29/2019		S4	875	D	$16.89(5)	252,767(12)	D
Common Stock	05/28/2019		S4	875	D	$16.94(6)	251,892(12)	D
Common Stock	06/27/2019		S4	875	D	$14.94(7)	251,017(12)	D
Common Stock	07/29/2019		S4	875	D	$13.7(8)	250,142(12)	D
Common Stock	08/27/2019		S4	875	D	$11.47(9)	249,267(12)	D
Common Stock	09/27/2019		S4	875	D	$14.68(10)	248,392(12)	D
Common Stock	10/28/2019		S4	875	D	$15.08(11)	247,517(12)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(13)	$35.53	04/06/2015		4A	30,000		(15)	04/06/2025	Common Stock	30,000	$0	30,000	D
Employee Stock Option (Right to Buy)(13)	$40	01/23/2016		4A	13,000		(16)	01/23/2026	Common Stock	13,000	$0	13,000	D
Employee Stock Option (Right to Buy)(13)	$20	04/11/2016		4A	40,000		(17)	04/11/2026	Common Stock	40,000	$0	40,000	D
Employee Stock Option (Right to Buy)(13)	$40	05/14/2017		4J(14)		13,000	(16)	01/23/2026	Common Stock	13,000	$0	0	D
Employee Stock Option (Right to Buy)(13)	$7.23						(18)	03/05/2023	Common Stock	5,300		5,300(24)	D
Employee Stock Option (Right to Buy)(13)	$5						(19)	01/03/2024	Common Stock	255,000		255,000(25)	D
Employee Stock Option (Right to Buy)(13)	$20.63						(20)	07/23/2021	Common Stock	15,000		15,000(26)	D
Employee Stock Option (Right to Buy)(13)	$20.63						(21)	08/14/2021	Common Stock	15,000		15,000(26)	D
Employee Stock Option (Right to Buy)(13)	$15.53						(22)	12/31/2021	Common Stock	105,800		105,800(26)	D
Employee Stock Option (Right to Buy)(13)	$12.55						01/21/2017	01/21/2027	Common Stock	30,000		30,000(27)	D
Employee Stock Option (Right to Buy)(13)	$12.4						(23)	03/03/2027	Common Stock	120,000		120,000(27)	D

Explanation of Responses:

1. As previously reported on the Reporting Person's Form 4 filed on April 3, 2017, on March 27, 2017, the Reporting Person was granted 120,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G1) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan (the "Plan"), which RSUs vest according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.

2. On January 25, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $17.69. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

3. On February 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $18.06. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

4. On March 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.80. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

5. On April 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.89. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

6. On May 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

7. On June 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

8. On July 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $13.70. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

9. On August 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $11.47. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

10. On September 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.68. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

11. On October 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $15.08. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

12. Due to administrative errors, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year was inaccurately reported in Column 5 of Table I of the Reporting Person's Form 5 filed on February 14, 2019 (the "2019 Form 5") and prior Section 16 reports. As a result, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year in Column 5 of Table I of this form does not correspond with the number reported in the 2019 Form 5. This form corrects the prior reporting and rounding errors made in Column 5 of Table I of the Reporting Person's prior Section 16 reports.

13. In the Reporting Person's prior Section 16 reports, employee stock options were referred to using various differing titles. For convenience, in the Reporting Person's future Section 16 reports, all employee stock options to buy common stock will be referred to using the title "Employee Stock Option (Right to Buy)." The nature and economic terms of the re titled employee stock options remain unchanged.

14. These derivatives securities were cancelled on May 14, 2017 and the Reporting Person received no value in connection with this cancellation.

15. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on July 29, 2016, on April 6, 2015, the Reporting Person was granted an employee stock option to purchase up to 30,000 shares of common stock, of which 9,000 shares vested and became fully exercisable on April 6, 2016; 9,000 shares vested and became fully exercisable on April 6, 2017; and 12,000 shares vested and became fully exercisable on April 6, 2018.

16. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on January 23, 2016, the Reporting Person was granted an employee stock option to purchase up to 13,000 shares of common stock, of which 3,900 shares vested and became fully exercisable on January 23, 2017; 3,900 shares vested and became fully exercisable on January 23, 2018; and 5,200 shares vested and became fully exercisable on January 23, 2019.

17. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on April 11, 2016, the Reporting Person was granted an employee stock option to purchase up to 40,000 shares of common stock, of which 12,000 shares vested and became fully exercisable on April 11, 2017; 12,000 shares vested and became fully exercisable on April 11, 2018; and 16,000 shares vested and became fully exercisable on April 11, 2019.

18. This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of March 5, 2013.

19. This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of January 3, 2014.

20. This option vested over a period of three years according to the following schedule: 1/3 on July 23, 2015 and 1/3 on each anniversary thereafter.

21. This option vested over a period of three years according to the following schedule: 1/3 on August 14, 2015 and 1/3 on each anniversary thereafter.

22. This option vested over a period of three years according to the following schedule: 1/3 on December 31, 2015 and 1/3 on each anniversary thereafter.

23. This option (Grant No. 14-324) vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.

24. The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 27, 2014. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.

25. The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 13, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.

26. The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 17, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.

27. The acquisition of these derivative securities was previously reported on the Reporting Person's Form 4 filed on April 3, 2017. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.

	/s/Bizuo (Tony) Liu	02/11/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.